title: Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer.
abstract: BACKGROUND
  To improve the prognosis of patients with urachal cancer and establish an effective chemotherapeutic regimen for distant metastases.
  
  
  METHODS
  We conducted a retrospective study to evaluate the efficacy and safety of a modified combination of 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) therapy in patients with metastatic urachal cancer.
  
  
  RESULTS
  Five patients were treated with mFOLFOX6. Their median age was 65 years (range 41-80). The median follow-up time was 42 months (range 18-46). Two of the 5 patients (40%) showed an objective response: 1 achieved a clinically complete response and 1 a partial response. The grade 3/4 toxicity associated with this regimen was primarily neutropenia, but febrile neutropenia was not observed. Oxaliplatin treatment was discontinued because of a grade 2 allergic reaction in 1 patient. Grade 2 peripheral sensory neuropathy caused by oxaliplatin was observed in 2 patients, and the OPTIMOX (stop and go) approach had to be adopted.
  
  
  CONCLUSIONS
  mFOLFOX6 appears to be effective for the treatment of metastatic urachal cancer.
authors: Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan.
authors: Yutaka
authors: Y
authors: Yanagihara
authors: Nozomu
authors: N
authors: Tanji
authors: Noriyoshi
authors: N
authors: Miura
authors: Akitomi
authors: A
authors: Shirato
authors: Kenichi
authors: K
authors: Nishimura
authors: Tetsuya
authors: T
authors: Fukumoto
authors: Koji
authors: K
authors: Azuma
authors: Yuki
authors: Y
authors: Miyauchi
authors: Tadahiko
authors: T
authors: Kikugawa
authors: Masayoshi
authors: M
authors: Yokoyama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin; D012189:Retrospective Studies; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil